• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ: PRTA )

15.22 -0.79 (-4.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
December 20, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
Demystifying Prothena Corp: Insights From 6 Analyst Reviews
December 20, 2024
Via Benzinga
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
December 19, 2024
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients. 
Via Investor's Business Daily
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
December 19, 2024
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses. 
Via Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
December 19, 2024
Via Benzinga
Expert Ratings For Prothena Corp
November 13, 2024
Via Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via Benzinga
Earnings Preview For Prothena Corp
November 11, 2024
Via Benzinga
Breaking Down Prothena Corp: 4 Analysts Share Their Views
October 01, 2024
Via Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
October 28, 2024
Via Benzinga
Dow Dips 300 Points; Emcore Shares Spike Higher
September 30, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
September 30, 2024
Via Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
September 30, 2024
Via Benzinga
Exposures Fossil Fuels
Demystifying Prothena Corp: Insights From 8 Analyst Reviews
March 13, 2024
Via Benzinga
Decoding 6 Analyst Evaluations For Prothena Corp
February 16, 2024
Via Benzinga
Prothena Corp: Q4 Earnings Insights
February 15, 2024
Via Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
PRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
June 11, 2024
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
PRTA stock results show that Prothena Corp missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
February 29, 2024
Via Benzinga
Earnings Outlook For Prothena Corp
February 14, 2024
Via Benzinga
Navigating 5 Analyst Ratings For Prothena Corp
January 25, 2024
Via Benzinga
$100 Invested In Prothena Corp 5 Years Ago Would Be Worth This Much Today
January 22, 2024
Via Benzinga
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 30, 2024
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales 
Via Benzinga
Demystifying Prothena Corp: Insights From 5 Analyst Reviews
January 09, 2024
Via Benzinga
Hewlett Packard Enterprise, Hologic And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
January 09, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 100 points on Tuesday. Shares of Hewlett Packard Enterprise Company (NYSE: HPE) shares fell sharply in pre-market... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 08, 2024
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 08, 2024
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap